

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

Claims 1-17 (cancelled).

Claim 18 (currently amended): An immunoassay method comprising the steps of:

- (a) reacting a monoclonal antibody specifically recognizing Phosphatidylinositol-3,4,5-triphosphate-phosphatidylinositol-3,4,5-triphosphate, or a variable region thereof, with phosphatidylinositol-3,4,5[[-3,4,5]]-triphosphate present in a sample; and,
- (b) detecting the binding based on an immunological reaction between said antibody, or said variable region thereof, and said phosphatidylinositol-3,4,5-triphosphate; wherein, said monoclonal antibody binds to an antigenic determinant that contains an inositol group and a glycerol backbone in said phosphatidylinositol-3,4,5-triphosphate.

Claim 19 (currently amended): The immunoassay method of claim 15 18, wherein said monoclonal antibody does not cross-react with phosphatidylinositol-4,5-biphosphate.

Claim 20 (currently amended): An immunoassay method which comprises the steps of:

- (a) reacting a monoclonal antibody specifically recognizing phosphatidylinositol-3,4,5-triphosphate, or a variable region thereof, with phosphatidylinositol-3,4,5-triphosphate present in a sample; and,
- (b) detecting the binding based on an immunological reaction between said antibody, or said variable region, thereof, and the triphosphate; wherein, said monoclonal antibody is comprises an immunoglobulin, or variable region thereof, which recognizes the phosphatidylinositol-3,4,5-triphosphate; wherein, said immunoglobulin, or said variable region thereof, comprises an immunoglobulin heavy chain comprising:
 - (i) CDR1 comprising the amino acid sequence of SEQ ID NO: 5;
 - (ii) CDR2 comprising the amino acid sequence of SEQ ID NO: 6; and,
 - (iii) CDR3 comprising the amino acid sequence of SEQ ID NO: 7.

Claim 21 (currently amended): The immunoassay method according to claim 1920, wherein said immunoglobulin comprises an immunoglobulin light chain comprising:

- (i) CDR1 comprising the amino acid sequence of SEQ ID NO: 8;
- (ii) CDR2 comprising the amino acid sequence of SEQ ID NO: 9; and,
- (iii) CDR3 comprising the amino acid sequence of SEQ ID NO: 10.

Claims 22-26 (cancelled).

Claims 27 (new): The immunoassay method of claim 18, wherein said method further comprises observing the degree to which the immunological reaction between the antibody, or variable region thereof, and an antigenic determinant recognized by said antibody, or said variable region thereof, is inhibited by phosphatidylinositol-3,4,5-triphosphate present in a sample.